Navigation Links
SyntheMed Announces FDA Clearance of SinusShield(TM)
Date:11/19/2008

ISELIN, N.J., Nov. 19 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that it has received FDA 510(k) clearance to market SinusShield(TM), a bioresorbable membrane intended to prevent post-operative adhesions in nasal and sinus surgical procedures. There are approximately two million nasal and sinus procedures performed annually in the United States.

Robert P. Hickey, SyntheMed's President & CEO stated, "SinusShield represents an example of our strategy to capitalize on our proprietary polymer film technology in new surgical applications both in the United States and international markets." The company is in discussion with prospective partners with the distribution infrastructure to service the office-based and hospital outpatient sites where these procedures are performed.

About SinusShield(TM)

SinusShield is a bioresorbable polymer membrane indicated for use in patients undergoing nasal and sinus surgical procedures as a space-occupying stent to separate and prevent adhesions between mucosal surfaces. During surgical procedures involving the sinuses and sinus passages, it is common for surgeons to place silastic tubes or sheets in the sinus passages to prevent blockage caused by adhesion formation; however, these materials must often be removed in a second procedure. SinusShield is intended to prevent blockage and then biodegrade thereby eliminating the second procedure.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products and other surgical implants based on its proprietary bioresorbable polymer technology. The company is developing a portfolio of anti-adhesion products led by REPEL-CV(R) Adhesion Barrier, an anti-adhesion product intended for use in open heart surgical procedures. REPEL-CV is currently marketed internationally and is
'/>"/>

SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. SyntheMed to Present at the Acumen BioFin Conference
3. SyntheMed Files Universal Shelf Registration
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
6. SyntheMed Completes $4.0 Million Equity Placement
7. SyntheMed Announces New Management Appointments
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to ... the Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment ... meals come from and how agriculture impacts their daily lives. This unique exhibit also ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a designer ... & Marketing Director. , With more than 25 years of experience in ... Tronics’ business development activities worldwide. He brings to the company his strong expertise ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... , July 30, 2015  With over 60,000 customers across the globe, ISN improves ... 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over ... Headquartered in Dallas, TX ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... Kristin Lucas, ClearTrial Senior Director of Clinical Services, will lead a ... Cash Flow and Accruals" at the CBI Forecasting & Budgeting conference. ... over clinical trial budgets and improve management of clinical trial cash ... ...
... of $0.44 -- increase of 110% from prior year , ... KNSY ), a leading medical technology company that provides ... today reported the results for its second quarter and first six ... , Record EPS of ...
... Calif., Jan. 28 NeuroFocus, the world leader in,the ... named,preeminent cognitive neuroscientist John Polich, Ph.D., as its Director ... company made this selection as it ramps up the ... the United Kingdom, France, Italy, Germany,Japan, Korea, India, and ...
Cached Biology Technology:ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference 2ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference 3Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 2Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 3Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 4Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 5Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 6Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 7Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 8Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 9Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 10Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 11Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 12Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 13Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 14Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 15Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 16Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 17Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 18NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations 2NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations 3
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... -- The Gladstone Institutes will receive funds totaling $5.6 ... major funding initiative focusing on HIV eradication. The funds ... biomedical-research organization, to explore the molecular basis for HIV ... within cells waiting for an opportunity to reemerge when ...
... testing biofilter systems as a viable alternative to releasing ... technology could reduce the overall impact of old landfills ... issue of the International Journal of Environmental Engineering ... sites generates a slow trickle of the potent greenhouse ...
... a high prevalence of vitamin D insufficiency and deficiency ... D levels was not observed in patients in southern ... Arthritis Care & Research , a journal of the ... between disease activity and vitamin D level. ...
Cached Biology News:Gladstone to receive $5.6 million in federal funds to seek a cure for AIDS 2Gladstone to receive $5.6 million in federal funds to seek a cure for AIDS 3Biofilters reduce carbon footprint of old landfill sites 2Vitamin D insufficiency prevalent among psoriatic arthritis suffers 2
... Kit, 1 kit. Convenient way ... Conjugations are carried out under mild ... Dyes are packaged in premeasured amounts ... Category: Blotting & Labeling & Detection, ...
...
Recombinant Mouse IL-23, CF...
...
Biology Products: